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The Journal of Immunology
Endothelial MAPKs Direct ICAM-1 Signaling to Divergent
Inflammatory Functions
Silvia Dragoni,1 Natalie Hudson,1,2 Bridget-Ann Kenny, Thomas Burgoyne,
Jenny A. McKenzie, Yadvinder Gill, Robert Blaber,3 Clare E. Futter, Peter Adamson,4
John Greenwood, and Patric Turowski
Lymphocyte transendothelial migration (TEM) is critically dependent on intraendothelial signaling triggered by adhesion to ICAM-1.
Here we show that endothelial MAPKs ERK, p38, and JNK mediate diapedesis-related and diapedesis-unrelated functions of ICAM-
1 in cerebral and dermal microvascular endothelial cells (MVECs). All three MAPKs were activated by ICAM-1 engagement, either
through lymphocyte adhesion or Ab-mediated clustering. MAPKs were involved in ICAM-1–dependent expression of TNF-a in cerebral
and dermal MVECs, and CXCL8, CCL3, CCL4, VCAM-1, and cyclooxygenase 2 (COX-2) in cerebral MVECs. Endothelial JNK and to
a much lesser degree p38 were the principal MAPKs involved in facilitating diapedesis of CD4+ lymphocytes across both types
of MVECs, whereas ERK was additionally required for TEM across dermal MVECs. JNK activity was critical for ICAM-1–induced
F-actin rearrangements. Furthermore, activation of endothelial ICAM-1/JNK led to phosphorylation of paxillin, its association with
VE-cadherin, and internalization of the latter. Importantly ICAM-1–induced phosphorylation of paxillin was required for lymphocyte
TEM and converged functionally with VE-cadherin phosphorylation. Taken together we conclude that during lymphocyte TEM, ICAM-1
signaling diverges into pathways regulating lymphocyte diapedesis, and other pathways modulating gene expression thereby contrib-
uting to the long-term inflammatory response of the endothelium. The Journal of Immunology, 2017, 198: 4074–4085.
T
ransendothelial migration (TEM) of leukocytes is well co-
ordinated and occurs during inflammation and homeostatic
immune surveillance of tissues. Initially, leukocytes adhere
loosely to the vascular wall and roll along its luminal surface before
being arrested by more firm adhesive interactions. They then undergo
diapedesis—the penetrative phase of passage through the endothelial
cell (EC) barrier (1). ICAM-1 and VCAM-1 on the surface of ECs
are key in mediating firm adhesion of leukocytes. ICAM-1 acts as
a gatekeeper of lymphocyte TEM (2) by binding to activated b2
integrins, namely LFA-1 (aLb2; CD18/CD11a). Following engage-
ment, ICAM-1 redistributes to perijunctional areas (3), which are
also the sites of active diapedesis (4).
ICAM-1 also initiates outside-in signaling that facilitates dia-
pedesis, increases vascular permeability, and regulates the endo-
thelial inflammatory response (2, 3, 5, 6). Endothelial signaling
downstream of ICAM-1 involves Rho GTPases, intracellular calcium
(Ca2+), endothelial NO synthase, actin cytoskeletal rearrangements,
protein kinase C (PKC) and Src family kinases. Many of these
components of ICAM-1 signaling are indispensable for lympho-
cyte TEM, both in vitro and in vivo (7–11). For the current study,
an important downstream effect of endothelial ICAM-1 activation
is phosphorylation of the adherens junction (AJ) component vas-
cular endothelial cadherin (VE-cad; cadherin 5), which is medi-
ated via Ca2+ and NO (3, 10, 12). In microvascular ECs (MVECs)
from the brain, ICAM-1 cross-linking also leads to phosphorylation
of the cytoskeletal scaffold protein paxillin via a Rho-dependent
pathway, which suggests a potential role for this protein during
lymphocyte TEM (7). Indeed, paxillin has recently been shown to
be required for neutrophil TEM across HUVECs (13). A plethora
of protein kinases, including focal adhesion kinase (FAK), Src,
and MAPKs, can phosphorylate paxillin on multiple sites (14).
Phosphorylation of Y31 and Y118 by FAK or Src are key for paxillin
function and its interactions with other proteins.
ICAM-1 activation also increases inflammatory gene expression,
e.g., that of IL-1B (15), CXCL8 (IL-8), CCL5 (RANTES) (16), and
VCAM-1 (17), although it is unclear how, or if, this relates to leukocyte
TEM.
The MAPKs ERK, p38, and JNK regulate numerous cellular
processes, including gene expression, cell survival, and cell motility
(18). As such, MAPKs mediate gene expression in ECs at various
levels (19). In addition, p38 controls posttranscriptional stabilization
of mRNAs that have AU-rich regions in their 39 untranslated region,
including transcripts for TNF-a and cyclo-oxygenase 2 (COX-2)
(20). All three endothelial MAPKs are activated in response to
ICAM-1 engagement, although the implication of this in relation to
TEM of lymphocytes is unclear. To this end, it has been shown that
ERK mediates ICAM-1–induced expression of VCAM-1 in HUVECs
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(17). In brain MVEC, activation of JNK in response to ICAM-1 en-
gagement occurs via a Rho-dependent pathway (7), which implies a
potential role in supporting TEM of lymphocytes. Finally, in TNF-a–
stimulated pulmonary MVECs, ICAM-1 engagement induces acti-
vation of p38 leading to actin cytoskeletal rearrangements and
phosphorylation of heat shock protein 27 (21).
We hypothesized that MAPKs are key regulators of diapedesis-
related and nondiapedesis-related processes during ICAM-1–
mediated TEM and investigated the roles of ERK, p38, and JNK
in response to ICAM-1 activation in cerebral and dermal MVECs.
We report that ERK, p38, and JNK were all involved in modulating
inflammatory gene expression. In contrast, TEM of lymphocytes
was mainly controlled by JNK, which in cerebral MVECs pro-
moted phosphorylation of paxillin and its subsequent interaction
with VE-cad.
Materials and Methods
Materials
Go¨6983, PP2, Mowiol 4-88, SB202190, and SP600125 were purchased
from Merck (Nottingham, U.K.); cell-permeable C3 transferase was from
Universal Biologicals (Cambridge, U.K.); PF573228 and FAK inhibitor 14
were from Tocris (Bristol, U.K.); U0126 was from Promega (Southampton,
U.K.); L-JNKi was from Alexis Biochemicals (Exeter, U.K.); actinomycin D,
myelin basic protein (MBP), and anti-tubulin ascites (clone DM1A) were
from Sigma (Poole, U.K.). Mouse anti-rat CD54 (clone 1A29), mouse anti-
human CD54 (clone 15.2), anti-rat CD18 (clone WT3), anti-rat CD11a (clone
WT1), and anti-rat CD49d were from AbD Serotec (Kidlington, U.K.). GST
c-Jun was purchased from Cell Signaling Technology (Hertfordshire, U.K.)
and GST-ATF2 from Upstate Biotechnology (Lake Placid, NY). Abs against
phosphorylated and total ERK, JNK, p38, and paxillin (Y118) were all from
Cell Signaling Technology (Hertfordshire, U.K.). Anti-phosphotyrosine
(clone 4G10) was from Millipore (Watford, U.K.) and anti-paxillin from
BD Transduction Laboratories (Oxford, U.K.). Affinity purified rabbit anti–
VE-cad has been described previously (22). Anti–VCAM-1 Abs were from
Santa Cruz Biotechnology (sc-1504). Additional reagents for indirect cell
immunochemistry included fluorescein-conjugated goat anti-rabbit IgG (MP
Biochemicals, Cappel), Cy3-conjugated goat anti-mouse IgG (Jackson
ImmunoResearch), and Zenon Alexa Fluor 546 Mouse IgG1 (Invitrogen,
Paisley, U.K.). HRP-coupled Abs for immunoblots were from GE Healthcare
(Buckinghamshire, U.K.).
EC culture
ECs were cultured on tissue culture plasticware (Nunc, Roskilde, Denmark)
coated with polymerized collagen I (BD Biosciences, Oxford, U.K.). The
immortalized rat brain MVEC line GPNT was maintained as previously
described (10). Primary cultures of rat brain MVECs (23) and the human
brain MVEC line hCMEC/D3 (24) were cultured in EGM2-MV medium
(Lonza, Slough, U.K.). Human dermal MVEC (PromoCell) were cultured
on tissue culture plasticware coated with gelatin (Sigma) and maintained in
EC growth media MV2 (PromoCell). Quality of EC cultures was routinely
assessed by visual inspection and transendothelial electrical resistance
(TEER) measurements (23). Importantly, none of the treatments (phar-
macological antagonists or transfections) had any effect on EC monolayer
integrity.
Lymphocyte coculture, adhesion, and TEM assays
Three different types of lymphocyte were used. Peripheral lymph node cells
(PLNCs) were isolated from cervical or juxtaintestinal lymph nodes of
Wistar or Lewis rats (Olac, Harlan) (3). PLNC cultures consist predomi-
nantly of nonantigen-activated lymphocytes, which do not display significant
TEM rates within 4 h of coculture with brain MVECs (25). The migratory
MBP-specific rat T cell line (PAS; a kind gift from Dr. E. Beraud, Marseille,
France) consists of clonal MHC class II–restricted CD4+ cells (26) that also
express IFN-g (Supplemental Fig. 3A) and can thus be classified as Th1.
Human CD4+ cells were isolated from peripheral blood using Ficoll Paque,
and positive selection on CD4+ MACS beads (Miltenyi, Bisley, U.K.) (10).
For rat brainMVECmonolayer stimulation and adhesion assays, PLNCs,
activated with 5 mg/ml Con A in EC-conditioned, serum-free growth medium,
and optionally fluorescently labeled with 1 mM calcein-AM (Invitrogen),
were used (3). For immunoblot analyses, PLNCs were added at a 5:1 ratio to
EC monolayers. At various times adherent PLNCs were extensively washed
off with ice-cold PBS before endothelial lysis to restrict studies to ECs (visual
inspection showed approximately one PLNC remaining per 250 ECs). For
some adhesion assays lymphocyte cell adhesion molecules were neutralized
using Abs. For this 13 107 PLNCs were incubated on ice for 1 h with 20 mg/ml
of anti–adhesion molecule Ab. Neutralization of LFA-1 was performed using
function-blocking Abs against CD18 and CD11a. This approach affects all b2
integrins (CD18). However, CD18/CD11a is the only b2 integrin expressed
on lymphocytes; the other three b2 integrins are only found in myeloid cells
(27). Function-blocking Abs against CD49d were used to neutralize VLA-4.
Migratory lymphocytes (rat PAS or humanCD4+) were cultured at 13106/ml
in RPMI 1640 supplemented with 10% FCS, 100 U/ml penicillin, 100 mg/ml
streptomycin, 1 mM sodium pyruvate, 1 mM nonessential amino acids, 2 mM
L-glutamine, and 50 mM b-mercaptoethanol in the presence of IL-2 (50 U/ml).
TEM assays were performed by time-lapsed video microscopy exactly as
previously described (3, 10).
ICAM-1 ligation, cross-linking, and small molecule
inhibitor pretreatment
ICAM-1 ligation or cross-linking was performed as previously described
(10). To study endothelial MAPK involvement, postconfluent, serum-
starved GPNTs were pretreated for 1 h with 50 mM U0126 (an inhibitor
of the ERK-activating kinase MEK), SP600125 (an inhibitor of JNK), and
SB202190 (an inhibitor of p38a and b) and then washed extensively. Due
to the presence of efflux pumps on brain MVECs, the extracellular con-
centration of inhibitors had to be relatively high to ensure MAPK activity
was significantly suppressed (Supplemental Fig. 2B–D).
Immunoblotting and protein kinase assays
Cell lysates were prepared as previously described (3). Proteins were
electrophoretically separated on SDS-polyacrylamide gels and immuno-
blotted (3, 10).
To assess intracellular MAPK activity, cells were lysed in ice-cold lysis
buffer containing 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 50 mM NaF,
10 mM b-glycerophosphate, 0.1 mM EDTA, 100 nM calyculin A, 1 mM
PMSF, 1 mM sodium orthovanadate, and 2 mg/ml each of pepstatin, aprotinin,
and leupeptin. Equal amounts of clarified lysates were then incubated with
1 mg anti-ERK, anti-JNK, or anti-p38 Ab and protein G–Sepharose beads.
Immunocomplexes were washed three times with lysis buffer and further
processed for kinase assays in 30 ml reaction volumes containing 25 mM
HEPES pH 7.5, 10 mM magnesium acetate, 5 mM of cAMP-dependent
protein kinase peptide inhibitor (PKI), 100 mM [g-[32P]]ATP (1000 Ci/mol),
and 1–5 mM of MBP, GST-c-Jun, or GST-ATF2 for ERK, JNK, or p38,
respectively. The mixture was incubated at 30˚C for 5–10 min, stopped
with 30 ml of 23 Laemmli sample buffer, boiled, and then analyzed by
SDS-PAGE and autoradiography. The amount of immunoprecipitated kinase
was determined by immunoblotting.
RT-PCR and RNA stability analyses
Total RNA fromGPNTs or PASwas prepared using the RNeasy kit (Qiagen,
Crawley, U.K.). Total RNA (0.25 mg for GPNT; 1 mg for PAS) was reverse
transcribed using Superscript III (Invitrogen). PCR reactions were per-
formed using 1 mg of cDNA and sequence-specific primers as detailed in
Supplemental Table I. Preliminary dose-response reactions ensured that
detection of each transcript occurred in the linear range of amplification
(data not shown). PCR products were separated by agarose gel electropho-
resis, stained with ethidium bromide, and acquired with GeneSys software
(Syngene). The m.w. of the PCR product was compared with the 100 bp DNA
ladder (New England BioLabs).
For RNA stability analyzes, total RNAwas isolated from GPNT cells at
various time points following transcriptional blockage through actinomycin
D treatment (10 mg/ml). Total RNA (1 mg) was DNase-treated and reverse
transcribed using a Quantitect Reverse Transcription Kit (Qiagen). For
TNF-a, cDNA was preamplified using Taqman PreAmp Mastermix (Applied
Biosystems, Paisley, U.K.) and RT-PCR was performed using Taqman Gene
Expression Assays (Assay ID Rn99999017_m1) according to the manufacturer’s
instructions (Applied Biosystems). COX-2 and ribosomal protein were ana-
lyzed using Power SYBR Green PCR Mastermix (Applied Biosystems). All
reactions were run on an ABI7900HT RT-PCR machine and results analyzed
using DART-PCR software.
ELISA and multianalyte flow assay
MVEC supernatants were collected after 4, 8, 12, 24, or 48 h of ICAM-1
cross-linking. ELISA was performed using the LEGEND MAX Human
TNF-a ELISA Kit with Precoated Plates (BioLegend) according to the
manufacturer’s instructions. Multianalyte flow assay of chemokines rele-
vant to neuroinflammation (28) was performed using the LEGENDplex
Multi-Analyte Flow Assay Kit (BioLegend). Optionally anti–TNF-a Abs
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(1 mg/ml; R&D Systems, Abingdon, U.K.) were added throughout the ICAM-1
stimulation period.
Plasmids, nucleofection, and luciferase assays
Plasmids encoding chicken (wild-type and dominant-negative Y31F/Y118F;
kindly provided by Dr. R. Horwitz, University of Virginia) (29) and human
paxillin (wild-type and S178A; kindly provided by Dr. K. Jacobson,
University of North Carolina), FLAG-tagged JNK1, JNK2, and MKK7
(wild-type and dominant-negative; kindly provided by Dr. R. Davis,
University of Massachusetts Medical School), and the pGL3-VCAM-1-
promoter-luciferase plasmid construct (pVCAM-1-luc; kindly provided
by Prof T. Minami, University of Tokyo, Japan) were nucleofected into
subconfluent GPNTs at 10 mg of plasmid per 33 106 ECs according to the
manufacturer’s instructions (Amaxa, Cologne, Germany). Transfection rates,
determined by indirect or direct fluorescent microscopy, were 60–80% except
for pVCAM-1-luc, which transfected at a slightly lower efficiency of 30–50%
(data not shown). Transfected cells were replated in full-growth medium and
experimental analysis was carried out 48 h later (3). Luciferase activity was
determined using a reporter assay system (Promega). All cells used in a
single experiment were derived from a single transfection and the same
number of cells was plated for each analysis point, which allowed direct
comparison of luciferase activity between samples.
Immunocytochemistry
Cells were fixed and processed for indirect immunocytochemistry of
F-actin using Alexa Fluor 488 phalloidin (1:50; Invitrogen) or Abs against
pan and phosphorylated paxillin (Cell Signaling Technology) as previ-
ously described (23). All immunostained preparations were further stained
with 1 mg/ml bisbenzimide (33258; Hoechst), mounted using Mowiol 4-88
and analyzed on a LSM 700 confocal laser-scanning microscope (Carl Zeiss,
Hertfordshire, U.K.). Images were acquired as 8-bit tif files and further
processed using Adobe Photoshop CS5 or National Institutes of Health
ImageJ 1.50c4.
VE-cad endocytosis
VE-cad internalization was monitored by two independent methods es-
sentially as described (30). For biochemical analysis live GPNT cells were
stimulated or not with anti–ICAM-1 Abs. After varying times, they were
washed three times with ice-cold PBS to stop any further endocytosis and
then incubated on ice with freshly prepared trypsin (1 mg/ml) for 30 min.
Reactions were stopped by the addition of soy bean trypsin inhibitor
(50 mg/ml). Cells were harvested by centrifugation, lysed, and analyzed
by immunoblot. Full-length, trypsin-resistant VE-cad was considered as
internalized.
Alternatively, confluent hCMEC/D3 were labeled with FITC-conjugated
anti–VE-cad Ab (Serotec rabbit anti-human CD144:FITC) on ice (to avoid
its internalization) for 1 h. Cells were washed and returned to 37˚C in the
presence or absence of anti–ICAM-1 Abs. Cells were fixed with 3.7%
formaldehyde, optionally after an acid wash in PBS, 25 mM glycine, 3%
BSA, pH 2.7 to remove extracellularly bound Ab (and to reveal exclusively
Ab bound to internalized VE-cad). Fixed cells were then processed for
image acquisition by confocal microscopy (see above).
Immunogold electron microscopy
hCMEC/D3 were fixed in 4% PFA and 0.1% glutaraldehyde and processed
as previously described (23). Sections of 80 nm thickness were then stained
using Abs against the extracellular domain (TEA 1.31; Serotech) or the C
terminus (sc-6458; Santa Cruz) of VE-cad. Samples were viewed on a Jeol
1010 TEM, and images were gathered using a Gatan OriusSC100B charge-
coupled device camera. Further image manipulation was performed in
Gatan Digital Micrograph and Adobe Photoshop. VE-cad distribution was
determined by visual inspection of electron micrographs. The distance of
gold particles from interendothelial junction areas was measured using
ImageJ.
Data and statistical analysis
Densitometric quantification of at least three independent immunoblots
were calculated and determined by changes in phosphoprotein content
normalized to tubulin/total paxillin loading controls, with values expressed
as fold increase. All numerical data were presented as mean 6 SEM. TEM
and adhesion data were expressed as percentage of control (TEM: mean 6
SEM of six replicates from at least six independent experiments; adhesion:
mean6 SEM of 12 replicates from three independent experiments). Statistics
were performed using one-way ANOVA, using the SPSS Statistics 17
software, with significance levels set at 0.05, followed by Student t test
(for pairwise comparison), Dunnett or Bonferroni post hoc analysis: ns,
p $ 0.05; *, p , 0.05; **, 0.001 , p , 0.01, ***, p # 0.001. Time-
dependent RNA decay data were analyzed by linear regression and
the significance of slopes determined by ANOVA: two-factor with
replication.
Results
ICAM-1 engagement on brain MVECs leads to MAPK
activation
Adhesion-dependent endothelial MAPK activation was studied in
cocultures of brain MVECs (GPNT) and Con A–activated PLNC
that adhere but do not undergo diapedesis (25). At least a 2-fold
increase in the amount of phosphorylated endothelial ERK, JNK,
and p38 was observed within 15 min of coculture, and this response
was sustained for at least 1 h (Fig. 1A). Ab-mediated neutralization
of LFA-1, the principal ICAM-1 counter receptor on lymphocytes,
reduced endothelial MAPK phosphorylation by at least 40% (Fig.
1B), whereas neutralization of VLA-4 had no effect on the increased
phosphorylation of endothelial MAPKs (Fig. 1C).
Stimulation of ICAM-1 on its own by Ab-mediated cross-linking,
which mimics the ICAM-1–relevant response of lymphocyte adhesion
(10), also increased the level of phosphorylated MAPKs (Fig. 2A).
This was not due to increased levels of each MAPK itself
(Supplemental Fig. 1A). The phosphorylation of p38 was induced
more rapidly and sustained for much longer than that observed for
ERK and JNK. Incubation with anti–ICAM-1 Ab alone (in the absence
of a secondary, cross-linking Ab) led to similar albeit more short-
lived activation of MAPKs (Fig. 2B). Incubation with an irrelevant,
isotype-matched Ab did not induce significant MAPK phosphory-
lation (Fig. 2C). Increased phosphorylation of endothelial MAPKs
was also observed following stimulation of ICAM-1 on primary rat
brain MVECs (Fig. 2D) or the human brain EC line hCMEC/D3
(Fig. 2E). MAPK kinases, in particular ERK, were also significantly
activated in primary human dermal MVECs (Fig. 2F, Supplemental
Fig. 1B), indicating that ICAM-1–induced MAPK activation was not
restricted to the brain endothelium. For all further experiments
ICAM-1 cross-linking was chosen to study long-term effects of MAPK
signaling whereas simple ICAM-1 ligation was used to reproduce
immediate early effects of ICAM-1 signaling.
Endothelial MAPKs regulate ICAM-1–induced gene expression
Next, we investigated changes in mRNA levels of various inflam-
matory genes in response to ICAM-1 activation. Cross-linking of
ICAM-1 for 4 h induced an ∼3-fold increase in VCAM-1, COX-2,
and TNF-a transcript levels (Fig. 3A). No changes were detected for
CCL2 or ICAM-1. Both in cerebral and dermal MVECs, ICAM-1
activation also led to increases in secreted TNF-a, which were
measurable within 4 h and sustained for at least 48 h (Fig. 3B, 3C).
Multiplex analysis further revealed significant upregulation of se-
creted CXCL8, CCL3, and CCL4 but not CXCL10, CCL2, or CCL5
in human cerebral MVECs (Fig. 3D, Supplemental Fig. 2A).
Whereas induction of CXCL8 was in part dependent on secreted
TNF-a, that of CCL3 and CCL4 was not. ICAM-1 activation did
not change production of any of these cytokines in human dermal
MVECs (Fig. 3E, Supplemental Fig. 2A). Induction of VCAM-1
expression following ICAM-1 cross-linking in GPNT was also
observed at the protein level (Fig. 3F). Pharmacological inhibition
of ERK, JNK, or p38 using U0126, SP600125, or SB202190,
respectively (see also Supplemental Fig. 2B–D), revealed a strong
dependency of VCAM-1 protein induction on ERK and p38 and to
a lesser degree JNK activity (Fig. 3F). In agreement, promoter
analysis using transiently transfected luciferase reporters showed
that ICAM-1 cross-linking enhanced the activity of the human
VCAM-1 promoter by 50% and that this response was abolished
by inhibition of ERK or p38, but not JNK (Fig. 3G).
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In contrast to VCAM-1, increases in mRNA levels of TNF-a and
COX-2 were only inhibited by the p38 inhibitor (Fig. 4A), sug-
gesting that they could be a result of enhanced message stabili-
zation (20). Message stability in response to ICAM-1 stimulation
was measured in transcriptionally blocked GPNT cells. The half-
life of TNF-a transcripts, which was 4.9 6 0.6 h in unstimulated
cells, increased to 12.9 6 3.8 h following ICAM-1 cross-linking
(Fig. 4B). This increased stability was sensitive to p38 inhibition.
The half-life of COX-2 transcripts, although very stable in the
absence of ICAM-1 cross-linking (half-life: 12.2 6 2.8 h), was
also further increased in a p38-sensitive manner following ICAM-1
cross-linking (Fig. 4C). Taken together we concluded that ICAM-1–
induced MAPK activation regulated inflammatory gene expression
through transcription and posttranscriptional mechanisms.
Endothelial JNK regulates lymphocyte transmigration
We next investigated whether endothelial gene expression was
critical for TEM of CD4+ Th1 cells across brain GPNT ECs.
Pretreatment of ECs with the transcription inhibitor actinomycin
D did not affect lymphocyte TEM, which occurred during the first
30 min of coculture (Fig. 5A). However, all subsequent TEM was
inhibited by actinomycin D. We conclude that in this model
of lymphocyte TEM initial diapedesis was independent of de novo
protein synthesis, whereas at the later time point the majority of
TEM required new protein synthesis.
Using U0126 we found that lymphocyte TEM across GPNT
did not require endothelial ERK (Fig. 5B). Inhibition of endo-
thelial p38 using SB202190 led to a weak (,10%) inhibition
of lymphocyte TEM. In contrast endothelial inhibition of JNK
using SP600125 reduced lymphocyte TEM by almost 50%. Sig-
nificant reduction in lymphocyte TEM with JNK inhibition
was also observed in SP600125-treated primary rat brain MVEC
(Fig. 5C) or when ECs were pretreated with the peptide inhib-
itor L-JNKi (Fig. 5D). In all cases the inhibition of endothelial
JNK reduced lymphocyte TEM without affecting adhesion
(Supplemental Fig. 3B–D). In addition, exogenous expression in
GPNTs of dominant-negative but not wild-type JNK1 or MKK7
reduced lymphocyte TEM (but not adhesion) by ∼60% (Fig. 5E,
Supplemental Fig. 3E). In contrast exogenous expression of
dominant-negative JNK2 did not significantly affect lymphocyte
TEM.
To study lymphocyte TEM in human cell models, CD4+ cells
isolated from human blood were allowed to transmigrate across
either cerebral hCMEC/D3 cells or primary human dermal MVECs.
MAPK dependency of TEM across human cerebral MVECs mir-
rored that observed for rat Th1/GPNT cocultures: TEM was very
sensitive to inhibition of endothelial JNK, to a much lesser degree
to inhibition of p38, and not at all to ERK inhibition (Fig. 5F). In
contrast, TEM of lymphocytes across human dermal MVECs was
sensitive (albeit to a lesser overall degree) to inhibition of JNK and
p38 as well as ERK (Fig. 5G), illustrating clear mechanistic dif-
ferences of TEM in cerebral and peripheral MVECs.
Src, Rho, and PKC are involved in ICAM-1–mediated
MAPK activation
Established endothelial ICAM-1 signaling effectors include Src,
Rho GTPase, and PKC (2). To examine how MAPK activation was
integrated into these signaling pathways, we used pharmacologi-
cal inhibitors in GPNT ECs. Inhibition of Src using PP2 abolished
ICAM-1–induced phosphorylation of all three endothelial MAPKs
(Fig. 6A). Inhibiting Rho GTPase using C3 transferase only af-
fected the phosphorylation of JNK, having no effect on the ICAM-
1–mediated increase in ERK or p38 phosphorylation (Fig. 6B). A
different pattern of inhibition was elicited by blocking PKC with
Go¨6983, whereby it prevented the activation of ERK and JNK, but
had no effect on p38 (Fig. 6C). None of the treatments affected
overall levels of MAPKs (Supplemental Fig. 1C). Inhibition of either
Src, Rho GTPase, or PKC in GPNT ECs also resulted in significant
inhibition of lymphocyte TEM without affecting adhesion to EC
monolayers (Fig. 6D, Supplemental Fig. 3F), in agreement with
FIGURE 1. Endothelial MAPK activation in response to lymphocyte adhesion. (A) All three MAPKs were activated in GPNT ECs cocultured with Con
A–activated, nonmigratory rat PLNCs. Shown are representative immunoblots of MAPKs phosphorylation alongside tubulin loading controls and normalized
densitometric quantification of three independent experiments. (B and C) MAPK activation in GPNT in 30 min cocultures was reduced when PLNCs were
preincubated with function-blocking anti–LFA-1 Abs but not an anti–VLA-4 blocking Ab. Shown are representative blots and densitometric quantification of
three independent experiments. Control phosphorylation levels (in response to PLNC adhesion without adhesion molecule neutralization) were set to 100%. Data
were compared with the corresponding time 0 controls and significant differences are indicated. In (C), white separation lines indicate where lanes from the same
blots were joined. *p , 0.05, **p , 0.01, ***p , 0.001.
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published data (8, 9, 12, 31) and indicating that they acted in
concert with JNK in regulating TEM.
Phosphorylation of paxillin via a JNK-dependent pathway
regulates lymphocyte TEM and VE-cad internalization in
cerebral MVECs
We next focused on the key role of JNK in lymphocyte TEM across
cerebral MVECs. Specifically, we investigated the relationship
between ICAM-1–mediated JNK activation and events critical to
TEM, namely endothelial actin reorganization as well as paxillin
and VE-cad phosphorylation (3, 9, 12, 13). Ligation of ICAM-1 in
GPNTs induced F-actin changes, with cortical bundles dominating
the cellular architecture after ∼20 min (Supplemental Fig. 3K).
Inhibition of JNK, but not ERK or p38, prevented this cortical
actin induction. Ab-mediated ligation of ICAM-1 also induced
robust phosphorylation of paxillin on Y118 (Fig. 7A, 7B), which
was abolished by inhibition of JNK. Exogenous expression of
Y31F/Y118F phosphorylation-deficient paxillin in ECs inhibited
lymphocyte TEM significantly by 42% (Fig. 7C), but had no effect
on adhesion (Supplemental Fig. 3G). In agreement, we found that
inhibition of endothelial FAK, which phosphorylates paxillin on
Y118 (14), also significantly reduced lymphocyte TEM (Fig. 7D,
Supplemental Fig. 3H). ICAM-1–induced phosphorylation of
paxillin occurred in the cell-cell contact areas of GPNT (Fig. 7E),
suggesting that ICAM-1–induced JNK-paxillin signaling was in-
volved in regulating endothelial junctions. Continuous strands of
phospho-paxillin staining could also be detected in the vicinity of
adherent PLNCs (Fig. 7F). These data prompted an analysis of the
association of paxillin with VE-cad during ICAM-1 activation and
TEM. As shown in Fig. 7G, ICAM-1 activation led to enhanced
association of VE-cad with paxillin, reaching peak levels after
around 10 min. This ICAM-1–induced association of VE-cad and
paxillin could be completely blocked by inhibition of JNK (Fig.
7H). In turn, MAPK inhibition did not affect ICAM-1–induced
VE-cad phosphorylation (Supplemental Fig. 3L).
The cooperation of paxillin and VE-cad was further confirmed in
TEM experiments of CD4+ Th1 lymphocytes across GPNT cell
monolayers. Inhibition of the paxillin activation pathway through
either SP600125 pretreatment or expression of Y31F/Y118F
paxillin led to TEM inhibition that was similar to that when the
VE-cad pathway was inhibited using either L-NAME pretreatment
(10) or expression of Y731F VE-cad (Fig. 7I, 7J). Combination of
treatments to inhibit both pathways did not result in additive effects,
indicating that paxillin and VE-cad phosphorylation functionally
FIGURE 2. Endothelial MAPK ac-
tivation in response to ICAM-1 liga-
tion and cross-linking. (A) GPNT were
subjected to ICAM-1 cross-linking
(XL), with secondary clustering, for the
indicated length of time and MAPK
phosphorylation analyzed. Representa-
tive results and quantification of kinase
activation (normalized mean 6 SEM)
from three independent experiments
are shown. (B) Representative analysis
of MAPK phosphorylation following
ICAM-1 ligation (without secondary
clustering) for the indicated times and
densitometric quantification of kinase
activation of three independent experi-
ments. MAPK levels were not signifi-
cantly affected by ICAM-1 ligation or
cross-linking (Supplemental Fig. 1A,
1B). (C) Postconfluent, serum-starved
GPNT cells were either left untreated or
incubated with 5 mg/ml anti–ICAM-1
(1A29) or isotype-matched control IgG
for 10 min. (D–F) Primary rat brain
MVEC (D) or hCMEC/D3 (E) or hu-
man dermal MVEC (F) were stimulated
by ICAM-1 cross-linking (XL) or
ICAM-1 ligation for the indicated times
and MAPK phosphorylation analyzed
as described in (B). Data were com-
pared with the corresponding time
0 controls and significant differences
are indicated. *p , 0.05, **p , 0.01,
***p , 0.001.
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converged during TEM. Taken together these data suggested that
ICAM-1/JNK activation mediated phosphorylation of paxillin and
its association with VE-cad to regulate lymphocyte TEM.
VE-cad has been shown to internalize during TEM (32). Here,
we show that ICAM-1 stimulation was sufficient to induce VE-cad
internalization. ICAM-1 stimulation increased the proportion of
VE-cad in GPNT cells that was resistant to trypsin treatment,
indicating it had been removed from the plasmalemmal surface
and internalized (Fig. 8A). Trypsin-resistant VE-cad increased
∼3-fold within 5 min of anti–ICAM-1 Ab addition (representing
∼4% of all cellular VE-cad). ICAM-1 stimulation also enhanced
endocytosis of a VE-cad–specific Ab in hCMEC/D3 cells, with
peak activity occurring at around 5–10 min (Fig. 8B). Further-
more, ultrastructural inspection by cryo-immuno–electron micros-
copy (EM) revealed a significant relocalization of VE-cad from
the junction to the cell interior by a distance of at least 50 nm
(Fig. 8C, 8D). Importantly within the context of our work,
ICAM-1–mediated VE-cad internalization was SP600125-sensitive,
indicating that it was under the control of JNK signaling (Fig. 8A).
VE-cad internalization also occurred in response to lymphocyte ad-
hering to brain ECs. Coculturing GPNT with nonmigratory PLNC for
15 min significantly increased trypsin-resistant VE-cad in SP600125-
sensitive manner (Fig. 8E). Microscopic analysis of cocultures of
hCMEC/D3 with human CD4+ cells revealed SP600125-sensitive
FIGURE 3. Role of MAPK in ICAM-1–mediated gene expression. (A) Total RNA was isolated from untreated (NT) or 4 h ICAM-1 cross-linked (XL)
GPNTs and analyzed by semiquantitative RT-PCR for message levels of VCAM-1, TNF-a, COX-2, CCL2, ICAM-1, and GAPDH. (B and C) Confluent
hCMEC/D3 (B) or human dermal MVEC (hDMEC) (C) were either left untreated or subjected to ICAM-1 cross-linking. At the indicated times TNF-a
concentration in the culture supernatant was determined by ELISA. Shown are mean levels 6 SEM of TNF-a above those in control cells from three
independent experiments. (D and E) hCMEC/D3 (D) or human dermal MVEC (hDMEC) (E) were left untreated (NT) or subjected to ICAM-1 cross-linking (XL)
for 24 h. The concentration of CXCL8, CXCL10, CCL2, CCL3, and CCL4 in the supernatant was measured by multianalyte flow assay. Where indicated anti–
TNF-a (1 mg/ml) was included during the stimulation period to determine if altered chemokine secretion was a consequence of TNF-a induction. Shown are
mean concentrations6 SEM of chemokines in the culture supernatant as determined from three independent experiments. (F) Confluent GPNT ECs were either
left untreated (NT) or treated with 200 U/ml TNF-a for 12 h or subjected to ICAM-1 cross-linking (XL) for 12 h prior to immunoblot analysis of VCAM-1 and
tubulin. Shown is a representative blot and densitometric quantification of three independent experiments. Where indicated cross-linking was performed in
the presence of 50 mM U0126, SP600125, or SB202190. White separation lines indicate where lanes from the same blots were joined. (G) GPNT ECs were
transiently nucleofected with pVCAM-1-luc, reseeded and allowed to grow to confluence (48–72 h posttransfection), and then subjected to ICAM-1 cross-
linking (XL) for 6 h or stimulation with IL-1b (IL1b). Where indicated cross-linking was performed in the presence of 50 mMU0126, SP600125, or SB202190.
Mean 6 SEM luciferase activity (relative to untreated cells) was determined from three independent experiments. *p , 0.05, **p , 0.01, ***p , 0.001.
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VE-cad endocytosis which occurred most strongly within the area of
the adhesion footprint of the lymphocyte (Fig. 8F). Taken together,
these results indicate that ICAM-1 via JNK and paxillin regulated
VE-cad internalization during TEM (Fig. 9).
Discussion
Endothelial ICAM-1 stimulation induces or enhances a variety of
inflammatory responses including vascular permeability, inflam-
matory gene expression, and the licensing of leukocyte TEM (2, 5,
6, 15, 16). However, the underlying signal transduction networks
responsible for these diverse effects are incompletely understood.
Here, we show interconnectivity of many previously recognized
components of ICAM-1 signaling through MAPKs, and attribute
diapedesis-related and diapedesis-unrelated functions (Fig. 9). The
MAPKs ERK, JNK, and p38 were activated in response to
lymphocyte adhesion, with signaling via ICAM-1 contributing
almost 50%. This is in line with previous reports of MAPKs as
important effector molecules of endothelial ICAM-1 signaling (7,
17, 21) and of other EC surface receptors (5). As in previous reports
MAPK activation was observed by receptor cross-linking (consisting
of a 30 min incubation with primary Ab followed by clustering with
a secondary Ab). Additionally, simple ICAM-1 ligation (10) (where
only the primary Ab is used) induced MAPKs with the only notable
difference being the length of their activation.
The balance of MAPK activation determines the inflammatory
state of the endothelium (19). In brain MVECs, MAPKs regulated
inflammatory gene expression in two ways. On the one hand, they
induced transcription of genes such as VCAM-1 consistent with
their ability to control the activity of transcription factors such as
AP-1 and NF-kB, binding sites for which are found in the VCAM-1
promoter (33, 34). Thus ICAM-1 signaling regulated micro-
vascular endothelial gene transcription in a way similar to that
reported for macrovascular HUVECs (17, 35). On the other hand,
ICAM-1 stimulation regulated gene expression in previously un-
recognized manner posttranscriptionally by significantly length-
ening the half-life of mRNAs encoding TNF-a and COX-2. This
is likely to occur via binding of proteins such as tristetraprolin,
human Ag R, and KH-type splicing regulatory protein to AU-rich
motifs in the 39 region of mRNAs encoding cytokines such as
COX-2 and TNF-a (20, 36). Importantly, mRNA stabilization
involving AU-rich motifs is heavily dependent on p38 activity and
this is exactly what we found for ICAM-1–induced stabilization of
messages. ICAM-1 stimulation induced inflammatory cytokines
relevant to neuroinflammation (28), including TNF-a, CXCL8,
CCL3, CCL4, and VCAM-1 but not CXCL10, CCL2, or CCL5.
TNF-a induction and secretion contributed in part to ICAM-1–
mediated CXCL8 upregulation in cerebral ECs. In dermal ECs
ICAM-1 also enhanced TNF-a secretion, albeit with a slower time
course, and there were no changes of the other cytokines tested,
indicating that ICAM-1 signaling induces fundamentally different
responses in different vascular beds. In prototypical neuroinflammatory
processes, such as multiple sclerosis, a wide range of chemokines is
found expressed by CNS parenchymal cells or infiltrated leukocytes
but importantly also ECs in the vicinity of lesions (28). Chemokine
expression such as CXCL8 by cerebral ECs themselves appears to
be important to bypass restrictions imposed by the blood-brain
barrier to take up, transport, and present parenchymally produced
factors. Although chemokine production of cerebral MVECs in re-
sponse to cytokine stimulation has been recognized for some time
(28), our data indicates that TEM alone also contributes to shaping
the inflammatory vascular fingerprint in the immediate vicinity of a
TEM event in the brain. Multiple types of leukocyte are capable
of crossing the same region of the vascular endothelium (37). For mul-
tiple sclerosis it is generally accepted that infiltration of autoantigen-
specific T lymphocytes [such as our PAS cells, which upon adoptive
transfer induce the model disease experimental autoimmune en-
cephalomyelitis (26)] precedes that of the main effector cells (mainly
monocytes but also B lymphocytes and neutrophils), which then
mediate devastating demyelination (38). Thus altered EC gene ex-
pression in response to ICAM-1 ligation may contribute to subse-
quent attraction of other leukocytes to sites of inflammation. These
may include neutrophils and monocytes given the strong induction
of CXCL8 and CCL3 and 4 (39, 40). Alternatively, because
FIGURE 4. ICAM-1–induced p38-mediated message stabilization. (A)
Levels of COX-2, TNF-a and GAPDH transcripts were determined by
semiquantitative RT-PCR analysis in response to ICAM-1 cross-linking
(XL) for 4 h. Where indicated cross-linking was performed in the presence
of 50 mM U0126, SP600125, or SB202190. (B and C) Confluent GPNT
cells were serum starved and either left untreated (NT, filled squares) or
ICAM-1 cross-linked (XL, filled triangles) in the absence or presence of
50 mM SB202190 (XL + SB, open triangles). Ten micrograms per milli-
liter actinomycin D was added to block transcriptional activity and total
RNA was isolated after 0, 2.5, and 5 h. Subsequently transcript levels of
TNF-a and COX-2 were determined by quantitative RT-PCR. The amount
of each transcript was quantified by densitometry, normalized, plotted, and
analyzed by linear regression and ANOVA. The values are mean 6 SEM
of seven (TNF-a) and five (COX-2) independent experiments. **p , 0.01,
***p , 0.001.
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lymphocytes have also been reported to express receptors for these
chemokines (40–43) initial T cell TEM may attract more T cells to
the permissive site identified by pioneering cells. Indeed, lymphocyte
TEM within a physiologically relevant timeframe of 30 min (44) did
not require gene transcription in cerebral ECs. However, subsequent
TEM events clearly needed endothelial de novo RNA synthesis,
suggesting that either turnover of the TEM machinery occurred at
later time points or that a secondary wave of lymphocytes required
the expression of certain EC molecules (such as chemokines or
VCAM-1). To our knowledge this is a novel paradigm likely to have
been overlooked in the majority of previous studies, which measured
rates after at least 4 h of coculture (e.g., 9, 45, 46).
FIGURE 5. Endothelial JNK regulates lymphocyte TEM. (A) GPNT monolayers were pretreated or not with actinomycin D (Act D, 5 mg/ml) and
subsequent TEM of Th1 lymphocytes (PAS, see also Supplemental Fig. 3A) measured after 30 min. Whereas Act D did not affect 30 min TEM rates, it
inhibited all subsequent TEM events (measured up until 4 h). (B) TEM assay as in (A) with the exception that GPNT monolayers were left untreated (NT) or
treated with 50 mM U0126 (U0), SP600125 (SP) or SB202190 (SB) for 1 h prior to a 30 min TEM assay. Due to the high washout rate of U0126 from
GPNT cells (see Supplemental Fig. 2B), TEM experiments were also conducted with U0126 present throughout. However, even under these conditions
TEM was not inhibited (data not shown). (C) TEM assay as in (B) except that primary rat brain MVEC were either left untreated (NT) or pretreated with
50 mM SP600125 for 1 h prior to addition of Ag-specific T lymphocytes. (D) TEM assay as in (B) with the exception that GPNTwere either left untreated
(NT) or treated with 1 mM L-JNKi for 1 h prior to the addition of T lymphocytes. (E) TEM assay as in (B) except that GPNT cells were transfected with
wild-type (WT) or dominant-negative (DN) JNK1, JNK2, or MKK7 48 h before TEM and adhesion were analyzed. (F and G) TEM assay as in (B) except
that TEM of human CD4+ cells across hCMEC/D3 (F) or human dermal MVEC (G) was measured following EC pretreatment with 50 mM U0126 (U0),
SP600125 (SP), or SB202190 (SB) for 1 h. *p , 0.05, **p , 0.01, ***p , 0.001.
FIGURE 6. Role of Src, Rho GTPase, and PKC in ICAM-1–mediated MAPK activation and lymphocyte TEM. Postconfluent, serum-starved GPNT cells were
either left untreated (NT) or pretreated with 10 mM PP2 for 30 min (A), 10 mg/ml C3 transferase for 12 h (B), or 20 mM Go¨6983 (Go¨) for 30 min (C). In (C) white
separation lines indicate where lanes from the same blots were joined. Where indicated EC monolayers were subjected to ICAM-1 cross-linking (XL) for 10 min.
MAPK phosphorylation was then analyzed and quantified as described for Fig. 1. Results similar to those shown with PP2 were also found with 10 mMSU6656 (data
not shown). MAPK levels were not significantly affected by any of the pretreatments (Supplemental Fig. 1C). (D) GPNT ECmonolayers were pretreated with 10 mM
PP2 for 1 h, 10 mg/ml C3 transferase for 16 h, or 20 mM Go¨6983 (Go¨) for 1 h prior to analysis of lymphocyte TEM. *p , 0.05, **p , 0.01, ***p , 0.001.
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FIGURE 7. Endothelial JNK mediates F-actin rearrangements and paxillin phosphorylation in the regulation of lymphocyte TEM. (A) GPNT cells were
pretreated without or with 50 mM SP600125 for 1 h before 30 min ICAM-1 ligation. Cell lysates were analyzed by immunoblots using anti–phospho-Y118
paxillin and anti-paxillin Abs. (B) Densitometric quantification of paxillin phosphorylation from three independent experiments as shown in (A). (C)
Expression of phosphorylation-deficient Y31F/Y118F (Y31/118F) significantly inhibited lymphocyte TEM (measured as described in Fig. 5E). (D) Pre-
treatment of GPNT with the FAK inhibitors PF573228 (PF, 10 mM) or FAK inhibitor 14 (C-14, 50 mM) for 1 h led to inhibition of TEM (measured as
described in Fig. 5B). (E) Postconfluent, serum-starved GPNT ECs were subjected to ICAM-1 ligation for 30 min, and then fixed and stained for phospho-
Y118 paxillin (green) and total paxillin (red). Shown are representative confocal micrographs. (F) Postconfluent GPNT monolayers were left untreated
(upper panels), or PLNCs (∼5 PLNCs per EC) were added (lower panels) and allowed to adhere for 30 min. Cultures were then vigorously washed to
remove all loosely attached PLNCs, fixed and stained for phospho-paxillin (red) and DNA (blue), and analyzed by confocal microscopy. Numbers indicate
three individual adherent T cells. Arrowheads indicate phospho-paxillin in cell-cell contact strands. Scale bars, 10 mm. (G) ICAM-1 was ligated in
postconfluent, serum-starved GPNT cells for the indicated times before the cells were lysed and VE-cad immunoprecipitated. Representative immunoblots
show the level of paxillin and VE-cad found in immunoprecipitates. Densitometric analysis (mean 6 SEM) from five such experiments is shown on the
right. (H) As in (G) with the exception that postconfluent GPNTwere pretreated with 50 mM SP600125 for 1 h and subjected to ICAM-1 ligation for 15 min
before analysis; quantification was from four independent experiments. (I) TEM assay as described in Fig. 5B except that GPNTs were pretreated with
50 mM SP600125 (SP), 1 mM L-NAME, or both as indicated. (J) TEM assay as described in Fig. 5E except that GPNTs were cotransfected with
combinations of plasmids encoding wild-type or phosphorylation-deficient Y31F/Y118F (Y31/118F) paxillin and wild-type or phosphorylation-deficient
Y731F mouse VE-cad as indicated. *p , 0.05, **p , 0.01, ***p , 0.001.
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Among the three MAPKs studied, endothelial JNK was most
important for facilitating lymphocyte TEM across both cerebral
and noncerebral ECs. The contribution of p38 was much weaker.
Significantly, in dermal MVECs where ERK was also much more
strongly activated by ICAM-1, ERK was also required for TEM
indicating that TEM differed at least in part across different vas-
cular beds. Given that both ERK and p38 have been reported to
regulate cytokine-stimulated TEM of neutrophils across non-
cerebral ECs (21, 47), MAPK requirements may depend on the
tissue context of the endothelium, its activation state, and/or the
leukocyte subtype undergoing TEM. Focusing further on the novel
role of JNK during TEM, we corroborated its role in cerebral
MVECs by expressing dominant-negatives of JNK1, JNK2, and
MKK7. These experiments also indicated that JNK1 rather than
JNK2 regulated lymphocyte TEM. JNK activation occurred
downstream of Src, Rho GTPase, and PKC, which are all involved
in regulating the TEM of various leukocyte subtypes across CNS
and non-CNS endothelium (2, 7–9, 31). Crucially, the key TEM
regulator Rho GTPase was not required for the activation of ERK
or p38, further underlining that these two MAPKs played a
minor or no role for TEM across cerebral ECs. Taken together,
these data firmly place JNK but not ERK or p38 at the center of
putative TEM licensing pathway(s) in the neural vasculature
(Fig. 9).
Paxillin phosphorylation downstream of ICAM-1 stimulation
has long been known (7). Recently a critical role for this cortical
scaffold protein and its upstream regulator FAK has also been
demonstrated in TEM of neutrophils (13). Our study validated the
involvement of paxillin/FAK for TEM across cerebral MVECs
and provided additional mechanistical details. ICAM-1–induced
phosphorylation of paxillin on Y118 was critical for TEM and
this was dependent on JNK activity. Notably, TEM was depen-
dent to the same extent on endothelial JNK activation as it was
on Y31/Y118 paxillin phosphorylation, suggesting that the latter
was a key effector process of endothelial JNK activation. Tyro-
sine phosphorylation of paxillin is often dependent on prior
FIGURE 8. ICAM-1 mediates VE-cad internalization in a JNK-dependent manner. (A) ICAM-1 was ligated in postconfluent, serum-starved GPNT. At
indicated times, cells were transferred to ice to stop endocytosis, treated with trypsin, and lysed, and the level of trypsin-resistant VE-cad determined by
immunoblot analysis. Shown are representative immunoblots and densitometric quantification of trypsin-resistant (i.e., internalized) VE-cad in comparison
with cellular tubulin content. A 10th of nontreated control cell extract was loaded to reveal total VE-cad content (no trypsin/10). Where indicated, cells
were pretreated with 50 mM SP600125. (B) VE-cad endocytosis was visualized by internalization of a FITC-labeled anti–VE-cad Ab (green) in post-
confluent, serum-starved hCMEC/D3 cells. Cells were left untreated or treated with anti–ICAM-1 (5 mg/ml) for the indicated times. Where indicated
extracellular Ab was removed by acid wash (AW). Subsequently cells were fixed, their nuclei counterstained (blue), and analyzed by confocal microscopy.
Scale bar, 10 mm. (C) Cryo-immuno–EM of VE-cad distribution in control (Ctrl) and anti–ICAM-1 stimulated (5 min) hCMEC/D3 cultures. Shown are
interendothelial junction areas with the two abutting plasma membranes. Arrowheads point out gold labeled VE-cad, which in control cells was found
predominantly associated with the plasmalemmal membrane (within 20 nm, i.e., the distance expected by the primary and the secondary bridging Ab) (23).
(D) Distances measured from cell-cell junction for VE-cad gold particles as determined from three independent preparations as shown in (C). (E) As in (A)
with the exception that postconfluent, serum-starved GPNTwere cocultured with PLNCs (∼5 PLNCs per EC) for 15 min. (F) hCMEC/D3 were cocultured
with human CD4+ lymphocytes (green) for 30 min. VE-cad (magenta) distribution and endocytosis was visualized as described in (B) by Ab labeling and
acid wash before fixation and confocal microscopy. Scale bar, 10 mm. *p , 0.05, **p , 0.01, ***p , 0.001.
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JNK-mediated serine phosphorylation (48). In agreement, we
found that expression of paxillin, phosphorylation-deficient on
the JNK-specific site S178, was as effective in inhibiting TEM as
was the tyrosine phosphorylation mutant (Supplemental Fig. 3I).
A similar JNK-dependent pathway has been shown to regulate
paxillin in normal rat kidney epithelial cells, where it is involved
in wound closure (49). Paxillin is mainly involved in the dynamic
regulation of focal adhesions and integrin-mediated cell motility
(14, 50). In cerebral MVECs, ICAM-1 stimulation or lymphocyte
adhesion resulted in the accumulation of tyrosine phosphorylated
paxillin at cell-cell junctions and association with VE-cad complexes.
Thus the current study adds to an increasing number of reports of
interactions of classical focal adhesion proteins with endothelial AJs
in the regulation of endothelial barrier function (51–54).
TEM licensing and the regulation of endothelial barrier function
are mechanistically related. Disruption or loosening of the AJs has
been observed during TEM in vitro (55). Likewise, vascular per-
meability is also accompanied by AJ disassembly (56) and im-
portantly can be induced by ICAM-1 stimulation and adherent
leukocytes (3, 6). In agreement, phosphorylation of VE-cad and its
subsequent internalization are hallmarks of both processes (3, 12,
30, 32, 56). Here, we show that ICAM-1-JNK-paxillin signaling
induced VE-cad internalization. During TEM, phosphorylation
and internalization may target VE-cad for degradation via an
endosome-lysosomal pathway and AJs may disassemble as a con-
sequence. Alternatively, VE-cad internalization may be part of dy-
namic rearrangements during the loosening of paracellular junctions.
Thus paracellular junctions are regulated by ICAM-1 during TEM
through at least two converging signaling pathways. First, VE-cad
phosphorylation is regulated through AMP–endothelial NO synthase
(10). Second, we show here that JNK-mediated association with
paxillin led to VE-cad internalization. Overall, our work lends fur-
ther evidence to a central role of VE-cad as a molecular and cellular
barrier function of ECs but also assigns a completely novel role to
paxillin in this process.
When examined by cryo-immuno–EM, much of the internalized
VE-cad was found in close proximity to the junction, suggesting
that it originated from the junction area itself. However, ICAM-1
stimulation clearly induced internalization throughout the EC.
Furthermore, in agreement with published data (32), internalized
VE-cad was detectable within the broader adhesion footprint of
the lymphocyte often being a considerable distance from the
paracellular junction area, raising the possibility that endosomal
VE-cad traveled much further or originated from nonjunctional
plasmalemmal membrane areas. Our studies focused on events
during lymphocyte adhesion and did not allow correlations to be
made between VE-cad internalization and the subsequent TEM
route. However, because all adherent lymphocytes appeared to
be associated with some internalized VE-cad and because TEM
across brain ECs is both paracellular and transcellular (57, 58),
VE-cad internalization is likely to be relevant to both TEM
routes.
In conclusion, the concomitant activation of MAPKs is cen-
tral to ICAM-1–mediated signaling in cerebral (Fig. 9) but also
in other vascular MVECs. Unsurprisingly, divergence was ob-
served in signaling and in downstream effector functions, with
all three MAPKs regulating transcription, solely p38 regulat-
ing posttranscriptional mRNA stabilization, and mainly JNK
regulating lymphocyte TEM. Future work should determine 1) if
a TEM event can prime subsequent TEM events through altered
endothelial gene expression; and 2) the role and endosomal
trafficking of vesicular VE-cad in the regulation of paracellular
and transcellular TEM (59).
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